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Hyperkalemia, if left untreated, can lead to sudden death
from cardiac arrhythmias. Hyperkalemia is defined as a
serum potassium concentration greater than 5.5 mEq/L.
It may develop when potassium intake exceeds excretion
or when the transcellular distribution of potassium is dis-
turbed.1,2 At our institution, hyperkalemia was the most
common adverse drug event (ADE). 
The clinical presentation of hyperkalemia is related to
the effects of high potassium levels on neuromuscular,
cardiac, and smooth muscle cells. Symptoms include
generalized fatigue, muscle weakness, twitching, pares-
thesias, nausea, cramping, paralysis, palpitations, and
cardiac abnormalities.1 Thrombocytosis, leukocytosis,
hemolysis, sickle cell disease, renal insufficiency or fail-
ure, Addison’s disease, hyporenin aldosteronism, pseu-
dohypoaldosteronism, insulin resistance or deficiency,
hypertonicity, rhabdomyolysis, burns, and trauma are
common causes of hyperkalemia.3 Medications can also
cause hyperkalemia through different mechanisms.
Drug-induced hyperkalemia can result from the use of
angiotensin-converting enzyme (ACE) inhibitors, an-
giotensin receptor blockers (ARBs), nonsteroidal antiin-
flammatory drugs (NSAIDS), aldosterone antagonists,
potassium supplements, nonselective β-blockers, heparin
(with prolonged use), tacrolimus, succinylcholine, peni-
cillin G potassium, pentamidine, ketoconazole, cy-
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Background: Hyperkalemia is one of the most common drug-related electrolyte abnormalities resulting in
adverse drug events (ADEs) at our institution. 
Objective: To determine the effect of a computerized pharmacy alert on the number of adverse events related
to hyperkalemia in a hospital setting and to study the impact of guidelines and education on pharmacist
response to high potassium levels. 
Methods: An alert was built into the pharmacy computer system, which warned pharmacists about a potassi-
um level greater than 5.1 mEq/L when processing an order that could increase potassium. The alert was
linked to a trigger medication list. After the alert was implemented, the number of ADEs due to hyperkalemia
was compared for the 3 months pre- and postalert. Due to a lack of consistency in pharmacist interventions
after implementation of the alert, hyperkalemia management guidelines were developed by the pharmacy
department. The staff pharmacists received training on how to address hyperkalemia when processing
prescriptions. After the education component was completed, the types of pharmacist interventions made
pre- and posttraining were also compared.
Results: Building an automated pop-up alert resulted in a decreased number of ADEs related to hyperkalemia 
(p < 0.001) and reduced the utilization of medications needed to treat hyperkalemia (p = 0.019).
Conclusions: Implementation of a computerized pharmacy alert resulted in a statistically significant decrease
in adverse drug events related to hyperkalemia in our institution. Educating pharmacists about hyperkalemia
and developing guidelines for its management provided consistency among responses to the high potassium
computerized alert. Further studies are needed to evaluate the impact of guideline development and
pharmacist education on the trend of drug-induced hyperkalemia in an inpatient pharmacy setting.
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closporine, trimethoprim, and digoxin.4 In addition, re-
cent studies have shown that the combination of spirono-
lactone and ACE inhibitors provides greater cardiovas-
cular protection in patients with congestive heart failure,
but it increases the risk of hyperkalemia. 
In previous literature, computerized alerts have been
reported to be beneficial, but many of the studies de-
scribe the impact of alerts on the physician side of order
entry, not at the point of pharmacist order entry or order
verification.5,6 A recent retrospective study demonstrated
that implementing computerized rules has the potential
to reduce the number of preventable ADEs in the long-
term care setting.7 The purpose of this study was to eval-
uate the impact of a computerized pharmacy alert on the
number of ADEs related to hyperkalemia in hospitalized
patients. In addition, we examined the effect of providing
hyperkalemia management guidelines and education on
pharmacist interventions for hyperkalemia. To our
knowledge, this is the first study to specifically describe
the impact of a computerized pharmacy alert on ADEs
due to hyperkalemia.
Materials and Methods
This work was conducted at a 504-bed, level II trauma
center in a large metropolitan area in southwest Florida.
In addition to treating trauma patients, internal medicine,
cardiology, neurology, and nephrology services are pro-
vided due to the hospital’s location within the community
and its being a teaching hospital. The pharmacy depart-
ment provides decentralized clinical services. Fifteen phar-
macists from both the day and night shifts contributed to
this work. The study was conducted in compliance with
the requirements of the facility’s institutional review
board. 
In August 2004, a computerized alert was developed
in the Cerner Millennium (version 10.1.13, Cerner Corp.,
Kansas City, MO) computer system used at our institu-
tion. The pharmacy and laboratory computer systems are
interfaced; thus, pharmacists were alerted of a potassium
level greater than 5.1 mEq/L while processing a trigger
medication order. The trigger medications were selected
based on the majority of hyperkalemia-related ADEs in
our institution. The medications included were ACE in-
hibitors, NSAIDS, aldosterone antagonists, trimetho-
prim/sulfamethoxazole, potassium supplements, and
ARBs. When a trigger medication order was entered, a
pop-up screen appeared on the computer, warning the
pharmacist about the patient’s last reported potassium
level (Figure 1). The pop-up screen also contained a re-
minder regarding where to document the response to the
alert. Pharmacists could override alerts as long as they
provided proper documentation and explained the rea-
soning behind their decisions. The number of computer-
ized alerts was retrieved through a report generated by
the information technology pharmacist.
To assess the impact of the alert, ADEs were moni-
tored for 3 months before (May–July 2004) and 3 months
after (September–November 2004) implementation of the
computerized alert. Since the alert was developed and
implemented during August, that month was not includ-
ed in the data analysis. Cases of hyperkalemia that oc-
curred in hospitalized patients while on any medication
that could increase potassium levels were included in the
ADEs reported. All patients admitted with preexisting
hyperkalemia were excluded from the study. An ADE
due to hyperkalemia was tracked when the patient re-
ceived an antidote for an elevated potassium level. Hy-
perkalemia cases were identified by investigating the rea-
son for administering antidote drugs such as sodium
polystyrene sulfonate, insulin and glucose, furosemide,
and calcium gluconate. Using antidote drugs as tracers
has been shown to increase the identification of adverse
drug events.8 The patient’s potassium level, serum creati-
nine, blood urea nitrogen, other medications, pharmacist
interventions, and outcomes were reviewed.
When assessing pharmacist interventions in the first
few months after implementing the alert, we noted a lack
of consistency in pharmacist response to the alert. Thus,
in November 2004, the management team of pharmacy
services developed hyperkalemia treatment guide-
lines1,2,9,10 to assist pharmacists in deciding whether the
medication ordered should be dispensed and what sug-
gestions they should provide to the physician when call-
ing regarding the hyperkalemia alert (Appendix I). For
critical conditions such as renal or congestive heart fail-
ure, cases were discussed with the specialist provider, as
recommended by the hyperkalemia treatment guide-
lines. Pharmacists were educated about the guidelines on
a one-on-one basis and had to pass a proficiency test
with a score greater than 70%. All pharmacists passed the
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Figure 1. Pharmacy alert as it appeared on the computer screen.
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proficiency test. A random sample of 15 interventions
that occurred before and after education was analyzed to
determine its effect. The number of times that pharma-
cists called the physician, the type of intervention recom-
mended, acceptance of the intervention, and the out-
comes were further documented. It was hoped that
educating pharmacists about the hyperkalemia treatment
guidelines would increase the frequency with which
pharmacists contacted physicians and made recommen-
dations regarding management of hyperkalemia.
STATISTICAL ANALYSIS
GraphPad software (GraphPad Software, La Jolla,
CA) was used to perform the statistical analysis. χ2 Analy-
sis was used to compare the number of ADEs that occurred
before implementation of the alert with the number that oc-
curred postimplementation. It was also used to evaluate
the effect of education on the pharmacists’ responses to the
high potassium level alert and its impact on the types of in-
terventions made in response to the pop-up screen.
Results
The potassium alert was tracked 63 times between
September and November 2004; 20 cases occurred during
order entry for a potassium supplement, 34 for an ACE in-
hibitor, 7 for an aldosterone antagonist, and 2 for an ARB. 
The number of ADEs caused by each drug class was
reviewed for the 3 months before and the 3 months after
the alert was built. Prior to implementation of the alert, 48
hospitalized patients had hyperkalemia that required treat-
ment with either sodium polystyrene sulfonate or dextrose
50% and insulin (Table 1). After the alert was implemented,
14 cases of hyperkalemia required treatment. Implementa-
tion of the alert showed a statistically significant decrease in
ADEs related to hyperkalemia (p < 0.001).
Of the 63 computerized alerts seen, 41 occurred prior
to the development of hyperkalemia treatment guide-
lines and 22 occurred afterward. In response to the alert,
pharmacists were to follow the guidelines developed by
the pharmacy administration. Recommended pharmacist
interventions included drug discontinuation, decrease in
the dose of the offending drug, treatment of hyper-
kalemia, or a combination of the above. Although the
numbers did not reach statistical significance, education
did appear to impact the number of times the pharma-
cists placed a call to the physician regarding hyper-
kalemia. Education also decreased the number of pa-
tients who required medication to treat hyperkalemia (p
= 0.019; Table 2). 
Discussion
Having the computerized alert in place resulted in a
statistically significant decrease in the number of ADEs
related to hyperkalemia at our institution, since pharma-
cists were driven to follow the alert when the screen ap-
peared and take the necessary steps to prevent an ADE.
If the pharmacist overrode the alert, the action had to be
documented.
Prior to the education phase, no standardized method
for management of hyperkalemia was available at our in-
stitution. The guidelines instructed the pharmacists to
call the physician directly and provided her or him with
the necessary information to treat hyperkalemia. Educa-
tion influenced the pharmacists’ actions, resulting in an
increased number of times that they called the physician
and made interventions. Only 15 cases were evaluated
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Table 2. Pharmacist Interventions Before and After
Education on Hyperkalemia Treatment Guidelines 
BEFORE AFTER 
INTERVENTION EDUCATION, n/N EDUCATION, n/N p VALUE
Physician called 8/15 12/15 0.245
Dosage decreased 1/8 1/12 1
Drug discontinued 5/8 2/12 0.062
Treatment received 6/8 2/12 0.019a
Intervention accepted 6/8 5/12 0.245
aStatistically significant decrease.
Table 1. Hyperkalemia-Related Adverse Drug Events
Before and After Potassium Alert 
DRUG CLASS BEFORE ALERT, n AFTER ALERT, n
ACE inhibitors 17 5
ARBs 3 1
Potassium supplements 22 6
Aldosterone antagonists 4 2
NSAIDs 2 0
ADEs 48 14
Admissions 4168 4273
ADEs/100 admissions 1.15 0.32a
ACE = angiotensin-converting enzyme; ADEs = adverse drug events; ARBs
= angiotensin receptor blockers; NSAIDs = nonsteroidal antiinflammatory
drugs.
ap < 0.001; statistically significant decrease. 
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for the periods before and after the education phase. A
larger number of cases may have demonstrated a greater
difference in pharmacist response during order entry of a
potentially hyperkalemia-causing drug. Only 2 out of 10
patients received treatment for hyperkalemia after phar-
macist education. This could be due to the fact that the
adopted potassium value that triggered an intervention
was 5.1 mEq/L. Even though pharmacists were calling
for levels that were above 5.1 mEq/L, physicians may have
decided against treating the patient and opted for monitor-
ing only for a potassium level less than 5.5 mEq/L. More-
over, giving the pharmacist more autonomy could have
helped in making a better impact on the number of ADEs.
For instance, in other local institutions, protocols were de-
veloped and approved by the pharmacy and therapeutics
committees to help guide pharmacist intervention when
hyperkalemia could be an issue. These programs made the
pharmacists more proactive at the order entry level and
gave them the liberty to act immediately. For example,
pharmacists had the authority to hold a medication; order
a serum creatinine level (if it was not already ordered); and
order a potassium level upon initiation of therapy that
might affect the potassium level, such as an ACE inhibitor
or a potassium supplement. 
Limitations of the study should be noted. The time pe-
riod studied was only 3 months before and 3 months after
the computerized alert was implemented. A longer period
might have provided a better evaluation of the effect of
such an alert. The computerized alert was set to appear
only when a trigger medication was ordered; it did not
alert the pharmacist if the potassium level increased while
the patient was on a medication that could increase the
potassium level. A list of drug-induced events related to
hyperkalemia was obtained from a computerized report
that included medications used for treating hyperkalemia,
such as sodium polystyrene sulfonate and dextrose 50%.
However, some patients may not have received sodium
polystyrene sulfonate or dextrose 50% for hyperkalemia.
They may have received furosemide or discontinued the
offending drug. Thus, some episodes of hyperkalemia may
have gone undetected. Another limitation of this study is
the potassium value that was set to trigger the alert. A
potassium value of 5.1 mEq/L might not have been high
enough to cause the physician to make changes in a pa-
tient’s medication regimen. For instance, in the “dose de-
creased” section of the pharmacist intervention, there was
not a statistically significant change before and after educa-
tion. This could be attributed to the fact that the potassium
level may not have been high enough for the physician to
be concerned and reduce the dose of the offending medica-
tion. Moreover, demographic data on the patients with hy-
perkalemia were not collected. The decrease in ADEs could
reflect differences in the hospitalized population at the
time of the study. 
The computerized alert was associated with a statisti-
cally significant decrease in the number of ADEs related
to hyperkalemia at our institution. Educating the phar-
macists about hyperkalemia treatment guidelines en-
couraged them to intervene in response to computerized
alerts about high potassium levels. Future development
of a protocol for management of hyperkalemia by phar-
macists would give pharmacists at the order entry level
the ability to make clinical decisions that may prevent
ADEs related to hyperkalemia.
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Appendix I. Hyperkalemia Guidelines
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